A Medtech start-up

An authentic breakthrough innovation

In 2005, a team led by Valerie Weaver (Berkeley) passed in vitro human breast cells from the normal state to the cancerous state and vice versa by playing on the pressure of the environment. This experience, confirmed since by many others, is a revolution in the understanding of cancer, at the same time it opens up prospects of unexpected therapy. Since its creation, CC&C has been translating the results of fundamental research into a therapeutic solution. We have also started mechanical oncology experiments no longer in test tubes but on animals. The main part of our efforts is to imagine, manufacture and test devices for exerting a field of constraint on a tumor.

A capitalized development

Like any independent start-up involving real innovation, we rely on capital increases to finance our research.

On the road to Proof of Efficacy

After the publication of our Proof of Concept in PlosOne (IF : 2,76) and the validation of our research axes by the scientific community, we began the search for public financing of our Proof of Efficacy, that is to say the transplant of human pancreatic cancer grafted in the pancreas of mice, which will then be treated by our technology, the objective being to prove that the treatment allows at least the control of the tumoral growth until the reduction of the size of the grafted tumor – and at best to obtain the restitution of the normal architecture of the pancreatic tissue, that is, healing. Our patent was issued in Japan and the USA, and is at the end of validation in the European zone, allowing us to secure our Industrial Property. A consortium was set up in Europe with teams from Bichat Hospital in Paris, one of the world leaders in Digestive Oncology. This large-scale experiment will allow us not only to obtain our Proof of Efficacy, but also to begin the devlopment of the Human Prototype, and to explore enhancement of the nanoparticles and the magnetic field gradient generator In parallel, we have also been working on the drafting of specifications for the realization of the Human prototype. It should be noted that field gradient generator prototypes for humans have already been developed and tested in MPI (Magnetic Particle Imagery), in particular by Philips and Bruker. That is reassuring news about the technical feasibility and toxicity of our device.

Adapted and flexible ecosystem

We have chosen to work in a network to add, on a case by case basis and according to needs, the skills we need.

A Medtech start-up

An authentic breakthrough innovation

In 2005, a team led by Valerie Weaver (Berkeley) passed in vitro human breast cells from the normal state to the cancerous state and vice versa by playing on the pressure of the environment. This experience, confirmed since by many others, is a revolution in the understanding of cancer,at the same time it opens up prospects of unexpected therapy. Since its creation, CC&C has been translating the results of fundamental research into a therapeutic solution. We have also started mechanical oncology experiments no longer in test tubes but on animals. The main part of our efforts is to imagine, manufacture and test devices for exerting a field of constraint on a tumor.

A capitalized development

Like any independent start-up involving real innovation, we rely on capital increases to finance our research.

On the road to Proof of Efficacy

After the publication of our Proof of Concept in PlosOne (IF : 2,76) and the validation of our research axes by the scientific community, we began the search for public financing of our Proof of Efficacy, that is to say the transplant of human pancreatic cancer grafted in the pancreas of mice, which will then be treated by our technology, the objective being to prove that the treatment allows at least the control of the tumoral growth until the reduction of the size of the grafted tumor – and at best to obtain the restitution of the normal architecture of the pancreatic tissue, that is, healing. Our patent was issued in Japan and the USA, and is at the end of validation in the European zone, allowing us to secure our Industrial Property. A consortium was set up in Europe with teams from Bichat Hospital in Paris, one of the world leaders in Digestive Oncology. This large-scale experiment will allow us not only to obtain our Proof of Efficacy, but also to begin the development of the Human Prototype, and to explore enhancement of the nanoparticles and the magnetic field gradient generator. In parallel, we are also working on the drafting of specifications for the realization of the human prototype. It should be noted that field gradient generator prototypes for humans have already been developed and tested in MPI (Magnetic Particle Imagery), in particular by Philips and Bruker. That is reassuring news about the technical feasibility and toxicity of our device.